Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has disclosed Total Current Liabilities for 8 consecutive years, with $35.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Current Liabilities fell 17.36% year-over-year to $35.2 million, compared with a TTM value of $35.2 million through Dec 2024, down 17.36%, and an annual FY2024 reading of $35.7 million, down 16.74% over the prior year.
  • Total Current Liabilities was $35.2 million for Q4 2024 at Innate Pharma, down from $42.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $91.4 million in Q4 2021 and bottomed at $35.2 million in Q4 2024.
  • Average Total Current Liabilities over 5 years is $53.1 million, with a median of $42.6 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities crashed 59.78% in 2020, then skyrocketed 68.5% in 2021.
  • Year by year, Total Current Liabilities stood at $54.2 million in 2020, then skyrocketed by 68.5% to $91.4 million in 2021, then crashed by 53.85% to $42.2 million in 2022, then increased by 1.12% to $42.6 million in 2023, then dropped by 17.36% to $35.2 million in 2024.
  • Business Quant data shows Total Current Liabilities for IPHA at $35.2 million in Q4 2024, $42.6 million in Q4 2023, and $42.2 million in Q4 2022.